

ACTION

It was pointed out that there were a number of inconsistencies in the referral of samples. The comforting fact was that there had not been any anti-HIV 2 positive results. It was agreed that this should be circulated to RTD's and ~~repeat~~ *repeat samples for the same donor* ~~tests~~ should be discouraged.

Dr. Gunson

- 6.4 It was agreed that pressures to use a combined test for anti-HIV 1/2 may occur during the year and this may be at an additional cost. Any such test should be evaluated at PHLS prior to introduction. Dr. Mortimer commented that the financing for the evaluation of test kits for anti-HIV had been withdrawn by the Supply Division of DOH. Dr. Gunson agreed to enquire into this.

Dr. Gunson

7. NON A, NON B HEPATITIS

- 7.1 Dr. Contreras outlined the results of the study in England and Wales (Appendix III).
- 7.2 Dr. Mitchell reported that in a Glasgow study of 5000 donations the ALT exceeded 50 i.u. in 2.8%. With respect to anti-HBc tests in a separate study, 17 out of 2000 donations were found positive, of which 15 were reproducible.
- 7.3 Prof. Cash reported that in Scotland the methodology for ALT testing had been examined and a standardised method had been agreed upon. This was available in the RTC's if ALT testing was agreed.
- 7.4 It was agreed that there should be no recommendation to institute ALT testing until the current study was completed in England. However, there was a degree of inevitability about the introduction of the test which was required by regulatory authorities in other countries to determine the acceptability of fractionated plasma products. This would be discussed with BPL in the near future.
- 7.5 Dr. Gunson reported that Ortho Pharmaceutical Company had approached him with respect to trials with the Chiron Test in the U.K. He would report on this later when further details were available.

I am opposed to this. We should not be thinking of selling fractions abroad. This is AGAINST self-sufficiency.

Dr. Gunson

8. TOPICS FOR FUTURE MEETINGS

- 8.1 HBV. Dr. Contreras would ask Dr. Barbara to report on the national testing of donors. HBV 2 should also be discussed.
- 8.2 ANTI-HBc. Dr. Follett would prepare a paper.
- 8.3 MALARIA

Dr. Contreras

Dr. Follett

NLN/ 5922

ACTION

9. DATE OF NEXT MEETING

Friday, 19th May, 1989, the National Directorate,
Manchester at 11.00 a.m.

(Dr. Contreras cannot attend on this day and it was agreed
that Dr. Barbara should attend in her place).

NLN/ 5923